We are live on
!
Find out more
KFO
Kopp Family Office Portfolio holdings
AUM
$163M
1-Year Est. Return
22.57%
This Fund
S&P 500
This Quarter
Est. Return
+41.59%
1 Year Est. Return
+22.57%
3 Year Est. Return
+33.98%
5 Year Est. Return
+1.93%
10 Year Est. Return
–
AUM
$246M
AUM Growth
+$61.4M
(+33%)
Cap. Flow
-$7.55M
Cap. Flow
% of AUM
-3.07%
Top 10 Holdings %
Top 10 Hldgs %
99.97%
Holding
13
New
–
Increased
1
Reduced
2
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$707K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NeoGenomics
NEO
|
+$6.97M |
| 2 |
XENT
Intersect ENT, Inc
XENT
|
+$1.29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95% |
| 2 | Technology | 4.72% |
Similar funds
OFM
PCR
TCGDR
IPWA
IVGAI
CC
GP
PWAM
Kopp Family Office's Q4 2020 Portfolio in Review
As of Q4 2020, Kopp Family Office held 13 positions worth $246M, up 33% from $184M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Kopp Family Office withdrew a net $7.55M in Q4 2020, reducing 2 holdings. Its largest reduction was NeoGenomics, cutting an estimated $6.97M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Technology.
Against the trend, Kopp Family Office added an estimated $707K to Horizon Therapeutics Public Limited Company Ordinary Shares.
- Kopp Family Office added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020, an estimated $707K increase.
- Kopp Family Office's biggest Q4 2020 reduction was NeoGenomics, cutting an estimated $6.97M.
- Kopp Family Office's ten largest holdings make up 100% of its $246M portfolio in Q4 2020.
- Kopp Family Office opened 0 new positions and closed 0 in Q4 2020.
- Kopp Family Office's portfolio value rose 33% quarter-over-quarter to $246M.
Based on Kopp Family Office's 13F filing for Q4 2020, filed 16 Feb 2021.